Quintiles Transitional Holdings Inc. (NYSE:Q) – Equities research analysts at Jefferies Group reduced their Q3 2017 earnings estimates for Quintiles Transitional Holdings in a research note issued on Thursday. Jefferies Group analyst D. Windley now expects that the medical research company will earn $1.13 per share for the quarter, down from their previous estimate of $1.20. Jefferies Group currently has a “Hold” rating and a $94.00 price target on the stock. Jefferies Group also issued estimates for Quintiles Transitional Holdings’ Q4 2017 earnings at $1.34 EPS, FY2017 earnings at $4.56 EPS, Q1 2018 earnings at $1.20 EPS, Q2 2018 earnings at $1.22 EPS, Q3 2018 earnings at $1.27 EPS, Q4 2018 earnings at $1.45 EPS and FY2019 earnings at $5.72 EPS.

Quintiles Transitional Holdings (NYSE:Q) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $1.09 EPS for the quarter, beating the consensus estimate of $1.05 by $0.04. Quintiles Transitional Holdings had a return on equity of 15.68% and a net margin of 0.82%. The firm had revenue of $1.97 billion during the quarter, compared to analyst estimates of $1.96 billion. During the same quarter in the prior year, the business posted $0.93 EPS. The business’s revenue for the quarter was up 68.7% compared to the same quarter last year. TRADEMARK VIOLATION NOTICE: “Brokers Set Expectations for Quintiles Transitional Holdings Inc.’s Q3 2017 Earnings (Q)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/07/brokers-set-expectations-for-quintiles-transitional-holdings-inc-s-q3-2017-earnings-q.html.

Several other equities research analysts have also recently issued reports on Q. Barclays PLC lifted their price objective on shares of Quintiles Transitional Holdings from $98.00 to $100.00 and gave the stock an “overweight” rating in a research report on Friday. William Blair raised shares of Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $70.10 to $93.42 in a research report on Friday. Stifel Nicolaus reaffirmed a “hold” rating and set a $92.00 price objective on shares of Quintiles Transitional Holdings in a research report on Friday. Zacks Investment Research cut shares of Quintiles Transitional Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $96.00 price objective (up from $94.00) on shares of Quintiles Transitional Holdings in a research report on Tuesday, June 6th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $89.88.

Shares of Quintiles Transitional Holdings (NYSE Q) opened at 90.42 on Monday. Quintiles Transitional Holdings has a one year low of $70.10 and a one year high of $93.53. The stock has a market cap of $19.90 billion, a price-to-earnings ratio of 200.04 and a beta of 0.64. The stock’s 50 day moving average price is $89.50 and its 200 day moving average price is $82.85.

Quintiles Transitional Holdings announced that its Board of Directors has approved a share repurchase plan on Wednesday, May 24th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 5.4% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its shares are undervalued.

In related news, major shareholder Cpp Investment Board Private H sold 7,131,165 shares of the business’s stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $84.01, for a total value of $599,089,171.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John G. Danhakl sold 761,143 shares of the business’s stock in a transaction on Tuesday, May 30th. The shares were sold at an average price of $84.01, for a total transaction of $63,943,623.43. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,758,400 shares of company stock valued at $735,783,985. 6.40% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in Q. Vanguard Group Inc. boosted its stake in shares of Quintiles Transitional Holdings by 0.9% in the first quarter. Vanguard Group Inc. now owns 12,508,830 shares of the medical research company’s stock worth $1,007,336,000 after buying an additional 113,613 shares during the last quarter. Longview Partners Guernsey LTD boosted its stake in shares of Quintiles Transitional Holdings by 6.2% in the second quarter. Longview Partners Guernsey LTD now owns 8,711,447 shares of the medical research company’s stock worth $779,675,000 after buying an additional 505,526 shares during the last quarter. Janus Capital Management LLC boosted its stake in shares of Quintiles Transitional Holdings by 0.4% in the first quarter. Janus Capital Management LLC now owns 7,783,546 shares of the medical research company’s stock worth $626,804,000 after buying an additional 27,675 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Quintiles Transitional Holdings by 4,217.1% in the first quarter. BlackRock Inc. now owns 7,098,723 shares of the medical research company’s stock worth $571,660,000 after buying an additional 6,934,290 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Quintiles Transitional Holdings by 2.6% in the first quarter. State Street Corp now owns 2,847,886 shares of the medical research company’s stock worth $229,337,000 after buying an additional 71,563 shares during the last quarter. 92.47% of the stock is owned by hedge funds and other institutional investors.

Quintiles Transitional Holdings Company Profile

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Earnings History and Estimates for Quintiles Transitional Holdings (NYSE:Q)

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.